Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients

Peio Errarte\textsuperscript{1,2,3}, Maider Beitia\textsuperscript{1,2,3}, Itxaro Perez\textsuperscript{1,2,3}, Lorea Manterola\textsuperscript{4}, Charles H. Lawrie\textsuperscript{4,5,6}, Jon Danel Solano-Iturri\textsuperscript{7}, Julio Calvete-Candenas\textsuperscript{7,8}, Miguel Unda\textsuperscript{9}, José I. López\textsuperscript{3,10}, Gorka Larrinaga\textsuperscript{1,2,3}\textsuperscript{*}

\textsuperscript{1} Department of Nursing I, Medicine and Nursing Faculty, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain, \textsuperscript{2} Department of Physiology, Medicine and Nursing Faculty, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain, \textsuperscript{3} BioCruces Research Institute, Barakaldo, Bizkaia, Spain, \textsuperscript{4} Molecular Oncology, Biodonostia Research Institute, Donostia, Gipuzkoa, Spain, \textsuperscript{5} Ikerbasque, Basque Foundation for Science, Bilbao, Spain, \textsuperscript{6} Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom, \textsuperscript{7} Department of Pathology, Basurto University Hospital, Bilbao, Bizkaia, Spain, \textsuperscript{8} Department of Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), Barakaldo, Bizkaia, Spain

\textsuperscript{*} gorka.larrinaga@ehu.eus

Abstract

The discovery of the intrarenal renin-angiotensin system (iRAS), which regulates angiogenesis, cell differentiation and proliferation, has opened new perspectives in the knowledge of kidney carcinogenesis. In this study we analyzed the immunohistochemical expression and fluorimetric activity of four key peptidases of iRAS in tumor tissue (n = 144) and serum samples (n = 128) from patients with renal neoplasms. Neutral endopeptidase (NEP/CD10), Angiotensin-converting enzyme-2 (ACE2), and aminopeptidase A (APA) were expressed in tumor cells whilst Angiotensin-converting enzyme (ACE) was expressed in the endothelial cells of intratumor blood vessels. The expression of ACE, ACE2 and NEP/CD10 was highest in clear cell renal cell carcinoma (CCRCC) and papillary renal cell carcinoma (PRCC). The expression of these enzymes correlated with CCRCC aggressiveness. In addition, NEP/CD10 correlated with 15-year overall survival. On the other hand, APA expression was decreased in CCRCC with higher grade and stage. The loss of expression of APA independently correlated with a worse 15-year overall survival. Serum activity of ACE2, NEP/CD10 and APA was significantly higher in renal tumor patients than in healthy subjects. Serum ACE activity was lower in high grade and metastatic CCRCC patients, and NEP/CD10 activity was negatively correlated with UISS (UCLA Integrated Staging System) and SSIGN (Mayo Clinic stage, size, grade and necrosis model) scores and with overall survival of CCRCC patients. These results suggest a metabolic imbalance of iRAS in renal tumors. This finding should be taken into account in the search of new diagnostic, prognostic and therapeutic tools for this disease.
Introduction

Renal cell carcinoma (RCC) is one of the top-ten most frequent malignancies in Western Countries. Moreover, epidemiological data reveal that its incidence has been steadily increasing in Europe and United States during the last years [1,2]. Clear cell renal cell carcinoma (CCRCC) is by far the most frequent histological subtype, accounting for approximately 75–80% of the cases, followed by papillary renal cell carcinoma (PRCC) (10–15%) [3]. Both types are proposed to originate from the proximal convoluted tubule [4]. Chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO), both originating from the intercalated cells of the distal nephron, are thought to share a common lineage and account for approximately 5% of the cases each [3,4].

RCC represents a major health problem primarily due to its resistance to current chemotherapy and radiotherapy protocols [3,5]. Presently, there are no clinical markers able to detect these diseases whilst asymptomatic and potentially curable. Only classic pathological parameters such as histological subtype, tumor stage and grade may be of help. However, these parameters give incomplete information since a significant percentage of renal tumors follow an unpredictable clinical course nowadays [3,6].

The renin-angiotensin system (RAS) was traditionally described as an endocrine pathway that regulates the hydro-electrolytic balance and the cardiovascular function [7]. However, recently the concept of RAS has undergone an extensive revision [8,9] to cover endocrine, paracrine, autocrine and intracrine functions regulating processes such as cell growth, proliferation and tissue repair [7,8] (see Fig 1). Imbalance in components of RAS has been associated with several chronic pathologies, including cancer [8,10,11].

The role of intrarenal RAS (iRAS) in renal carcinogenesis has been suggested by epidemiological [12–14], translational [15–18] and clinical evidences [19,20]. We have described in previous studies that the enzymatic activities of several angiotensin-regulating peptidases were significantly lower in different renal tumor subtypes when compared with the uninvolved surrounding renal tissues [21–25]. Some of these changes in enzyme activity correlated with protein and mRNA expression and were associated with tumor aggressiveness and survival [21–25].

We analyze here the immunohistochemical expression of four crucial peptidases in RAS [neutral endopeptidase/CD10 (NEP/CD10), angiotensin-converting enzyme-2 (ACE2), aminopeptidase A (APA), and angiotensin-converting enzyme (ACE)] in a retrospective series of 144 RCCs, and the fluorimetric activity of these enzymes in prospectively collected serum of 128 RCC patients. The three most common renal carcinomas (clear cell, papillary, chromophobe renal cell carcinomas) and the renal oncocytoma have been included in this study. In order to examine prognostic potential of these biomarkers we studied their relationship with survival in CCRCC cases.

Materials and methods

Patients

Samples and data from patients included in this study were provided by the Basque Biobank for Research OEHUN (http://www.biobancovasco.org). All patients were informed about the potential use for research of their surgically rejected tissues, and accepted this eventuality by signing a specific document approved by the Ethical and Scientific Committees of the Basque Country Health System (Osakidetza). (CEIC 2015/060, CEIC-E PI2015101 and CEIC 11–51).

Formalin fixed and paraffin embedded samples from renal tumors of 144 patients surgically treated at Cruces University Hospital between 1997 and 2001 were retrospectively selected for...
the study and re-reviewed under the microscope for diagnostic consistency by an experienced uropathologist. Clinical follow-up extended from RCC diagnostic data to December 31, 2015. American Joint Committee on Cancer (AJCC) [26] and Furhman’s [27] methods were applied to assign Stage and Grade, respectively.

In addition, serum samples from 128 patients, diagnosed with RCC between 2012 and 2016 in Basurto University Hospital, were collected preoperatively. Clinical follow-up extended from RCC diagnostic data to December 31, 2016. Serum from 40 healthy volunteers with no clinical history of neoplastic diseases was used as control sample (male/female 21/19, age 55.6/59.3 years). Serum samples were from CCRCC patients with a short follow-up (average: 32.7 months). So, we used two validated scales that predict patients’ relapse probability: the UCLA Integrated Staging System (UISS) model [28], and the Mayo Clinic stage, size, grade, necrosis (SSIGN) model [29].
Table 1 summarizes the clinical and histological characteristics of patients with renal tumors.

|                  | CCRCC Patients | Tissue samples | Serum samples |
|------------------|----------------|----------------|---------------|
|                  | Average (range)| Average (range)| Average (range)|
| **Age (range)**  | 70.69 (39–93)  | 61.42 (36–82)  |               |
| **Sex (Male/Female)** | 76/26         | 60/29          |               |
| **Follow-up (months)** | 110.3 (7–204) | 32.27 (1–57)   |               |
| **Survival**     |                |                |               |
| Alive            | 64             | 75             |               |
| Dead of disease  | 38             | 14             |               |
| **Diameter**     |                |                |               |
| ≤4 cm            | 35             | 28             |               |
| >4 to 7 cm       | 33             | 39             |               |
| >7 cm            | 34             | 22             |               |
| **Grade**        |                |                |               |
| G1               | 21             | 2              |               |
| G2               | 45             | 46             |               |
| G3               | 22             | 30             |               |
| G4               | 14             | 10             |               |
| **pT**           |                |                |               |
| pT1              | 59             | 59             |               |
| pT2              | 13             | 12             |               |
| pT3              | 28             | 16             |               |
| pT4              | 2              | 2              |               |
| **PRCC Patients**|                |                |               |
| **Age (range)**  | 74.79 (58–89)  | 54.0 (26–80)   |               |
| **Sex (Male/Female)** | 17/4          | 17/4           |               |
| **ChRCC Patients**|              |                |               |
| **Age (range)**  | 73.41 (58–94)  | 64.625 (47–74) |               |
| **Sex (Male/Female)** | 11/6          | 7/1            |               |
| **OR Patients**  |                |                |               |
| **Age (range)**  | 84.25 (74–93)  | 63.45 (40–84)  |               |
| **Sex (Male/Female)** | 4/0           | 3/7            |               |

Table 1 summarizesthe clinical and histological characteristics of patients with renal tumors.

Tissue microarray (TMA) construction and NEP/CD10, ACE2, APA and ACE immunohistochemistry

Four tissue microarrays (TMA) were prepared for the study. Each TMA was constructed by transferring a representative part of 42 different RCC samples into a paraffin block. H&E staining was performed in order to select high tumor load (>70%) areas. Each TMA also included a set of 4 non-tumor tissue samples (2 samples from non-tumor renal tissue adjacent to two renal tumors and 2 samples of normal renal tissue from nephrectomies performed for non-tumor diseases). Non-tumor tissue controls were obtained from the same cases in the 4 TMAs.

Immunohistochemistry was performed using an automated immunostainer (AutoStainer Link 48 Dako, Glostrup, Denmark) under standard protocols for research antibodies. After deparaffination and rehydration, optimal antigen retrieval was performed in DAKO’s PT Link...
pretreatment module and low pH target retrieval solution. Retrieved slides were incubated with antibodies against NEP/CD10 (SPM118, Santa Cruz Biotechnologies; 1:100), ACE2 (AC18Z, Santa Cruz Biotechnologies; 1:50), APA (Abcam; 1:250) and ACE (2E2), Abcam; 1:20). Characteristics of each antibody are detailed in S1 Table. EnVision Flex visualization system was used as suppliers recommend. Negative controls were processed under the same conditions as the test slides with the only difference that weren’t exposed to the primary antibody.

**NEP/CD10, APA ACE and ACE2 activity measurements**

Each enzyme activity was measured in triplicate by fluorometric assays in a FluoStar Optima microplate Reader (BMG Labtech, Ortenberg, Germany). Assays are based on the measurement of the fluorescence of products generated by each enzyme activity at saturating concentrations of specific substrates.

For NEP/CD10 activity measurement, method designed by Florentin et al. was employed [30]. Briefly, 30 μl of sample were incubated with 1mM of N-dansyl-D-Ala-Gly-p NO2-Phe-Gly (DAGNPG, a dansyl derivative, Sigma-Aldrich). After 30 min at 37˚C generated [D]AG fluorescence intensity was measured at 560 nm with excitation at 340 nm. Thyrophan, a recognized enkephalinase inhibitor was used in a concentration of 10 μM for inhibition assays, with a 93% success.

Aminopeptidase A activity was measured by a modified version of Tobe et al’s method [31]. 10 μl of serum sample were incubated with Glu-β-naphthylamide (0.227 mM) (Sigma-Aldrich), 30 min at 37˚C in a final volume of 200 μl. Fluorescence intensity of generated β-naphthylamide was measured at 410 nm wavelength with excitation at 340 nm. Inhibition assays to ensure assay specificity were performed with fenantrone 1,2 mM, obtaining an inhibition of the 87% of total activity.

ACE and ACE2 activity was estimated by measuring the fluorescence intensity of the product generated by the hydrolysis of their respective specific substrates Abz-Gly-Phe(NO2)-Pro and Abz-Ser-Pro-NTyr-OH (Bachem). ACE was measured following the protocol designed by Santandreu et al. [32]. 50 μl of sample were incubated in a final volume of 300 μl with 0.45 mM of specific substrate for 30 min. at 37˚C. For ACE2 activity measurement, a modified version of the method described by Yan ZH et al. [33] was used, incubating 30 μl of sample in 100μl of 0.5mM substrate for 2h at 37˚C. Fluorescence intensity was measured in an excitation wavelength of 360 nm and emission at 410 nm in both assays. Substrate specificity was checked by inhibition assays with captopril for ACE and DX600 for ACE2. Total inhibition was observed in both cases when 10 μM and 1 μM of inhibitor were added respectively.

Blanks consisted of buffer (instead the sample) and the same reactive and were used to determine background fluorescence. Relative fluorescence was converted into picomoles of product using a standard curve constructed with increasing concentrations of β-naphthylamine (1.5–500 μM) [D]AG (0.625–150 μM) or Abz-Gly-OH (2.5–300 μM).

**Statistical analysis**

SPSS® 22.0 software (IBM, Madrid, Spain) was used to perform statistical data analysis. A Kolmogorov-Smirnov test was applied to data obtained from tissue and serum samples to determine whether the numbers followed or not a normal distribution. Based on this information, data were analyzed with non-parametric tests. We performed Spearman Rho correlation test to evaluate the correlation between RAS enzyme expression and activities, and patient age and gender. Mann-Whitney U test (Mann-U) was used to detect differences in serum enzyme activity from RCC patients and their controls, and from patients with CCRCCs with different tumor size (more or less than 7cm), grade [G1/2 (low) vs. G3/4 (high)] and stage [pT1/2...
organ confined) vs. pT3/4 (non-organ confined). Kruskal-Wallis test was applied to analyze serum activity differences in patients with different renal tumor subtypes and in CCRCC patients with different UISS and SSIGN scores. Chi-square ($\chi^2$) test was used to compare enzyme expression in different histological parameters and to analyze the relationship between categorical enzyme expression (negative or positive) and pathologic variables of CCRCC tissues.

Finally, Kaplan-Meier curves and log-rank test were performed to evaluate the association between the expression and activity of angiotensin-regulating enzymes and overall survival of CCRCC patients. Groups were created by cut-off points based on categorical enzyme expression and median of enzyme activity values. A Cox regression model (univariate and multivariate) was used to test the independent effects of clinical and pathological variables and peptidase expression/activity on survival.

A p-value lower than 0.05 ($p<0.05$) was considered a statistically significant result for all statistical analysis.

**Results**

Expression of RAS enzymes in different subtypes of renal tumors and in their adjacent non-tumor tissues (Fig 2)

NEP/CD10 immunostaining was positive in proximal convoluted tubules of the normal kidney (Fig 2F), as well as in almost half of studied CCRCC (membranous) (Fig 2G) and PRCC (apical membranous) samples (Fig 2H). By contrast, it was negative in ChRCC (Fig 2I) and RO (Fig 2J). ACE2 immunostaining was positive also in proximal convoluted tubules of the normal kidney (Fig 2K), as well as in CCRCC (membranous) (Fig 2L) and PRCC (apical membranous) (Fig 2M). On the contrary, it was negative in almost 60% of ChRCC (Fig 2N) and all RO (Fig 2O). APA immunostaining was diffusely positive in normal kidney (tubules and glomeruli) (Fig 2P), as well as in CCRCC (membranous) (Fig 2Q), PRCC (membranous) (Fig 2R), ChRCC (membranous and cytoplasmic) (Fig 2S) and RO (cytoplasmic) (Fig 2T). ACE immunostaining was positive in proximal convoluted tubules of the normal kidney (Fig 2U). Tumor cells from all CCRCC (Fig 2V), PRCC (Fig 2W), ChRCC (Fig 2X) and RO (Fig 2Y) were negative. However, in CCRCC, neoplastic blood capillaries were positive (Fig 2V).

Expression of both NEP/CD10 and ACE2 were variable in RCC histotypes (chi-square $\chi^2$ test $p = 0.006$ for both markers) (Table 2). Half of the CCRCC (45.6%) and PRCC (42.9%) expressed NEP/CD10. In contrast, very few ChRCC (5.9%) and no RO cases expressed it. Differences were significant between CCRCC and ChRCC (chi-square $\chi^2$ test $p = 0.002$), PRCC and RO ($p = 0.01$), and almost between CCRCC and RO ($p = 0.07$).

Similarly, roughly two thirds of CCRCCs and PRCCs expressed ACE2, whereas less than a half of ChRCC and no RO did it (Table 2). Statistically significant differences were founded when CCRCC was compared with ChRCC (chi-square $\chi^2$ test $p = 0.021$) and RO ($p = 0.003$), and between PRCC and RO ($p = 0.023$).

APA expression was detected in more than 75% renal tumors studied and no significant differences in the expression of APA were observed among histological subtypes. ACE, in contrast, was expressed in almost a half of CCRCCs (Table 2), whereas the other histological subtypes were almost all negative in PRCC (chi-square $\chi^2$ test $p = 0.002$) and ChRCC ($p = 0.017$), or negative in RO ($p = 0.1$).

**RAS enzymes expression in CCRCC patients according to clinical and pathologic variables.** There was not any correlation between enzyme expression and patients' sex and age (Spearman Rho test $p>0.05$ for all cases).
Fig 2. Plate showing the hematoxylin and eosin (H&E) staining of normal kidney (A), clear cell renal cell carcinoma (CCRCC) (B), papillary renal cell carcinoma (PRCC) (C), chromophobe renal cell carcinoma (ChRCC) (D) and renal oncocytoma (RO) (E) and immunohistochemical pattern displayed for four peptidases (NEP/CD10, ACE2, APA and ACE) (test performed in formalin-fixed and paraffin-embedded material). NEP/CD10 immunostaining was positive in proximal convoluted tubules of the normal kidney (F), as well as in about half CCRCC (membranous) (G) and PRCC (apical membranous) studied samples (H). By contrast, it was negative in ChRCC (I) and RO (J). ACE2 immunostaining was positive also in proximal convoluted tubules of the normal kidney (K), as well as in CCRCC (membranous) (L) and PRCC (apical membranous) (M). By contrast, it was negative in almost 60% of ChRCC (N) and in all RO (O). APA immunostaining was diffusely positive in normal kidney (tubules and glomeruli) (P), as well as in CCRCC (membranous) (Q), PRCC (membranous) (R), ChRCC (membranous and cytoplasmic) (S) and RO (cytoplasmic) (T). ACE immunostaining was positive in proximal convoluted tubules of the normal kidney (U). All CCRCC (V), PRCC (W), ChRCC (X) and RO (Y) were negative. Only neoplastic blood capillaries were positive in CCRCC (V). (Original magnification, x20 for uninvolved renal tissues, and x400 for tumors).

Table 2. Expression of RAS enzymes on RCC according to histological subtype. NEP/CD10, ACE2 and APA expression was studied in renal carcinoma cells while ACE expression was in intratumor blood vessels.

| Histologic subtype | NEP/CD10 | ACE2 | APA | ACE |
|--------------------|----------|------|-----|-----|
|                    | Neg (%)  | Pos (%) | P value | Neg (%)  | Pos (%) | P value | Neg (%)  | Pos (%) | P value | Neg (%)  | Pos (%) | P value |
| CCRCC              | 102      | 54.4  | 45.6 | 0.006 | 30.1    | 69.9    | 0.006 | 20.6    | 79.4    | 0.334 | 99      | 57.4  | 42.6 | 0.002 |
| PRCC               | 21       | 57.1  | 42.9 |        | 38.1    | 61.9    |        | 14.3    | 85.7    |        | 19      | 94.7  | 5.3  |       |
| ChRCC              | 17       | 94.1  | 5.9  |        | 58.8    | 41.2    |        | 17.6    | 82.4    |        | 17      | 88.2  | 11.8 |       |
| RO                 | 4        | 100.0 | 0.0  |        | 100.0   | 0.0     |        | 25.0    | 75.0    |        | 3       | 100.0 | 0.0  |       |

https://doi.org/10.1371/journal.pone.0181711.t002

https://doi.org/10.1371/journal.pone.0181711.g002
In contrast, the expression of RAS enzymes correlated significantly with pathological parameters of tumor aggressiveness such as histologic grade, stage and size (Fig 3).

Thus, when data were stratified by histologic Grade (Fig 3A), significant differences were observed for NEP/CD10 (chi-square $\chi^2$ test p = 0.0001), ACE2 (chi-square $\chi^2$ test p = 0.029) and APA (chi-square $\chi^2$ test p = 0.0002). When comparisons were performed between two groups, NEP/CD10 expression was significantly lower in G1 than in the rest tumor grades (G1 vs G2 p = 0.000062; G1 vs G3 p = 0.000051; G1 vs G4 p = 0.017). ACE2 showed similar results (G1 vs G2 p = 0.011; G1 vs G3 p = 0.021; G1 vs G4 p = 0.036). On the contrary, APA expression in tumor cells decreased while tumor grades increased (G1 vs G3 p = 0.006; G1 vs G4 p = 0.00011; G2 vs G4 p = 0.001). We also observed lower ACE expression in blood vessels from G1 than in higher grade CCRCCs when data were compared between two groups (G1 vs G2 p = 0.044; G1 vs G3 p = 0.043).

With respect to tumor stage (Fig 3B), APA expression was decreased in higher stage CCRCCs (chi-square $\chi^2$ test p = 0.024). This difference was significant between pT1 and pT3 tumors (p = 0.005), and almost significant between pT1 and pT2 (p = 0.06), and pT1 and pT4 (p = 0.04). We did not found any significant result for NEP/CD10 (p = 0.178), ACE2 (p = 0.65) and ACE (p = 0.525).

Regarding tumor size (Fig 3C), results were stratified in three groups following previously reported classifications [28, 34]: tumors with 4cm or smaller, 4 to 7cm tumors, and tumors larger than 7cm. APA and ACE expression showed statistically significant differences (chi-square $\chi^2$ test p = 0.001 and p = 0.044, respectively). APA expression was higher in CCRCCs smaller than 4cm with respect to tumors between 4-7cm (p = 0.019) and larger than 7cm (p = 0.0003). Inversely, ACE expression was lower in CCRCCs smaller than 4cm with respect to tumors between 4-7cm (p = 0.014). NEP/CD10 (p = 0.12) and ACE2 (p = 0.24) did not throw significant results.

**Tissue RAS enzyme expression associated with overall survival in CCRCC patients.**

Expression of NEP/CD10 in tumors was associated with worse survival (log-rank p = 0.007) (Fig 4A) (Table 3). Inversely, APA expression was correlated with better survival of CCRCC patients (log-rank p = 0.001). ACE2 and ACE expression did not correlate with patient survival. (Table 3).

By univariate analysis, overall survival correlated with tumor diameter, grade, pathologic stage, and NEP and APA expression. These variables were included in the Cox regression multivariate analysis and results indicated that tumor stage (pT), NEP and almost APA expression were independent prognostic factors predicting CCRCC patients’ survival (Table 4).

**Serum activity of RAS enzymes in patients with renal tumors with respect to healthy subjects**

Serum activity of NEP/CD10, ACE2 and APA and was higher in patients with renal tumors than in healthy subjects. This result was statistically significant for NEP/CD10 only in CCRCC patients; in all of tumor subtypes for ACE2; and in patients with CCRCC, PRCC and RO for APA (Table 5). ACE activity was lower in ChRCC and RO than in controls, however, this difference did not reach statistical significance.

**Activity of angiotensin-regulating enzymes in serum of CCRCC patients according to clinical and pathologic variables**

There was no correlation between the activity of serum RAS enzymes and sex and age of CCRCC patients (Spearman Rho test p > 0.05 for all cases). We neither found any significant result when data were stratified by tumor size (Kruskal-Wallis p > 0.05).
Fig 3. Expression of RAS enzymes in CCRCC according to Fuhrman’s grade (A), AJCC tumor stage (B) and tumor size (C). Percentage of positive (black) samples for each enzyme are represented in figure bars. Histological grade (G1-G4), pathological stage (pT1-pT4) and tumor size (≤4cm - 4cm<x≤7cm->7cm) intergroup differences were evaluated using $\chi^2$ test. Statistically significant correlations are highlighted in bold. Statistically significant differences between two specific groups were also analyzed using $\chi^2$ test (**p<0.01; (***)p<0.005).

https://doi.org/10.1371/journal.pone.0181711.g003
Serum activity of RAS enzymes correlated with pathological parameters of tumor aggressiveness. Thus, lower ACE activity was observed in serum from patients with high grades (G1/G2 717.38 ± 187.94 vs G3/G4 634,5 ± 192,592; Mann-U p = 0.029) and metastatic CCRCC (local disease 706,1 ± 192,81 vs metastatic disease 565.18 ± 147.05; Mann-U p = 0.009). NEP/CD10 activity showed a similar trend, although this result did not reach statistical significance. Activity of the other two enzymes didn’t show statistically significant results when stratified with these variables.

When NEP/CD10 activity was stratified by SSIGN model, which predicts progression of CCRCC after radical nephrectomy [29], lower activity was measured in the group of patients with high (= 2) or intermediate (= 1) progression risk when compared with lower (= 0) progression risk group (Fig 5A) (Kruskal-Wallis test p = 0.03). And stratified by UISS score, NEP/CD10 activity in serum from patients with high mortality risk (= 2) was also lower than in patients with low (= 0) and intermediate (= 1) mortality risk (Fig 5B) (Kruskal-Wallis test p = 0.007).

Table 3. Log-rank and cut-off values for angiotensin-regulating enzymes predicting overall survival of CCRCC patients. Statistically significant are highlighted in bold.

| IHC Expression | Cut-off value | Log-rank p = |
|---------------|--------------|-------------|
| NEP/CD10      | Pos/Neg      | 0.007       |
| ACE2          | Pos/Neg      | 0.177       |
| APA           | Pos/Neg      | 0.001       |
| ACE           | Pos/Neg      | 0.219       |

| Enzyme activity | Cut-off value | Log-rank p = |
|-----------------|---------------|-------------|
| NEP/CD10        | 7350          | 0.007       |
| ACE2            | 730           | 0.518       |
| APA             | 2350          | 0.52        |
| ACE             | 650           | 0.206       |

https://doi.org/10.1371/journal.pone.0181711.t003
Activity of the other 3 enzymes didn’t show statistically significant results when stratified with these predictive models.

RAS enzyme activity according to overall survival of CCRCC patients

The analysis of NEP/CD10 activity in serum samples displayed opposite results to those obtained in tumor tissue. Thus, when serum NEP/CD10 activity was lower than 7350 UP/L, the overall survival was significantly worse according to Kaplan-Meier curves (Fig 6A) (log-rank, \( p = 0.007 \)).

Table 4. Univariate and multivariate analysis (Cox regression model) of clinicopathological variables and NEP/CD10 and APA expression predicting overall survival of patients with CCRCC. Statistically significant correlations are highlighted in bold.

| Variables      | Univariate analysis | Multivariate analysis for NEP/CD10 | Multivariate analysis for APA |
|----------------|---------------------|------------------------------------|-------------------------------|
|                | p value             | OR                                 | p value | OR               | p value | OR               |
| Sex            | 0.911               | 1.042                              | -                   | -               | -                   |
| Age            | 0.064               | 1.026                              | -                   | -               | -                   |
| Diameter       | 0.000001            | 2.83                               | 0.327              | 1.335           | 0.863              | 1.054                |
| \(<4\) cm      |                     |                                    |                    |                 |                     |
| \(>4\) to 7cm  |                     |                                    |                    |                 |                     |
| \(>7\) cm      |                     |                                    |                    |                 |                     |
| Grade          | 0.000019            | 2.047                              | 0.421              | 1.194           | 0.533              | 1.144                |
| G1             |                     |                                    |                    |                 |                     |
| G2             |                     |                                    |                    |                 |                     |
| G3             |                     |                                    |                    |                 |                     |
| G4             |                     |                                    |                    |                 |                     |
| Stage          | 5.24 \(10^{-10}\)   | 3.395                              | \(0.001\)          | 2.534           | \(0.00014\)       | 1.054                |
| pT1            |                     |                                    |                    |                 |                     |
| pT2            |                     |                                    |                    |                 |                     |
| pT3            |                     |                                    |                    |                 |                     |
| pT4            |                     |                                    |                    |                 |                     |
| NEP/CD10 expression | 0.003              | 2.886                              | 0.047              | 2.001           | -                   | -                   |
| Positive       |                     |                                    |                    |                 |                     |
| Negative       |                     |                                    |                    |                 |                     |
| APA expression | 0.001               | 0.295                              | -                   | -               | 0.063              | 0.473                |
| Positive       |                     |                                    |                    |                 |                     |
| Negative       |                     |                                    |                    |                 |                     |

NEP/CD10 activity was higher in patients with CCRCC than in healthy subjects, ACE2 activity was higher in all histological subtypes and APA was higher in CCRCC, PRCC and RO patients. Values are means \( \pm SE \) of units of peptidase per liter of plasma (UP/L). Statistically significant results are highlighted in bold (Mann-\( U \) \( p<0.05 \), \( \ast \), \( p<0.01 \), \( \ast\ast \), \( p<0.001 \), \( \ast\ast\ast \)).

Table 5. Serum activity of RAS enzymes on renal tumor patients and healthy controls.

|                | Control | CCRCC       | PRCC       | ChRCC       | RO        |
|----------------|---------|-------------|------------|-------------|-----------|
| NEP/CD10       | 7183.58 \(\pm 605.6\) | 7453.01 \(\pm 733.7\)* | 7028.14 \(\pm 1085.4\) | 7402.25 \(\pm 519.7\) | 7516.55 \(\pm 422.5\) |
| APA            | 2087.6 \(\pm 401.6\) | 2486.55 \(\pm 656.7\)* ** | 2562.95 \(\pm 596.0\)* ** | 2408.75 \(\pm 573.1\) | 2528.45 \(\pm 633.1\)* ** |
| ACE2           | 549.00 \(\pm 206.15\) | 767.96\(\pm 304.4\)* *** | 875.66\(\pm 520.17\)* *** | 666.00\(\pm 160.36\)* | 662.9\(\pm 112.7\)* ** |
| ACE            | 619.4 \(\pm 238.8\) | 679.18\(\pm 192.4\) | 659.24\(\pm 195.4\) | 513.25\(\pm 124.7\) | 562.64\(\pm 147.3\) |

https://doi.org/10.1371/journal.pone.0181711.t004

https://doi.org/10.1371/journal.pone.0181711.t005
Univariate analysis showed that tumor diameter, grade, pT, distant metastases, UISS and SSIGN scores, NEP/CD10 activity and almost patients' age are associated with overall survival. These variables were included in the Cox multivariate analysis and a stepwise selection procedure (backward conditional method) was used to select the optimal predictive model. This

Fig 5. Serum activity of NEP/CD10 in CCRCC patients according to UISS and SSIGN scores. Kruskal-Wallis test showed statistically significant differences both for NEP/CD10 activity stratified by SSIGN (p = 0.03) and UISS (p = 0.027). By SSIGN score, differences were founded between low progression patient group and high progression patient group (Mann-U, p = 0.014). By UISS score, differences were detected between high mortality risk group when compared with low (Mann-U, p = 0.008) and intermediate (Mann-U, p = 0.022) risk groups. Values are means ± SE of units of peptidase per liter of plasma (UP/L).

https://doi.org/10.1371/journal.pone.0181711.g005
analysis showed that UISS (p = 0.001) and SSIGN (p = 0.09) scores were the most relevant variables predicting CCRCC patients' survival, although SSIGN score did not achieve statistical significance.

**Discussion**

A wide variety of tissues and organs express all the components of the RAS, where they have important homeostatic functions in cell differentiation and proliferation. In contrast their deregulation may contribute to the development and progression of proliferative disorders [8,11]. The discovery of an intrarenal RAS (iRAS) has been crucial to understanding the renoprotective effect of ACE inhibitors (ACEi) and Ang II receptor blockers (ARB) in non neoplastic kidney diseases with fibrotic and proliferative characteristics such as diabetic nephropathy [35]. Additionally, it has opened new perspectives in kidney carcinogenetic processes and in the potential usefulness of these drugs in renal cancer [13–18,20].
Angiogenesis is a key factor in RCC development [36]. Increasing evidence demonstrates that imbalances in RAS favoring the ACE–Ang II–AT1 receptor axis play a critical role in vascular endothelial growth factor (VEGF)-dependent angiogenesis [8,10,11]. It has been described that the expression of AT1 and AT2 receptors correlates with tumor grade and with worse survival in CCRCC patients [16]. Recent studies in xenograft models of human RCC have showed that the blockade of this axis with ACEi and ARB decreases tumor diameter, vascularization and metastatic capacity, and enhances the antiangiogenic effect of sunitinib [15,17]. Moreover, retrospective analyses [12,14] and a clinical trial [20] have demonstrated that the use of RAS inhibitors improves survival in metastatic CCRCC patients receiving VEGF-targeted therapy.

We reported previously that ACE activity was higher in high grade CCRCC tissue homogenates than in low grade ones [24]. Interestingly, ACE was not expressed in tumor cells but rather in endothelial cells, suggesting that the source of ACE activity was the tumor vasculature. However, the immunohistochemical analysis of this study was performed in few prospectively collected cases [24]. In the present study we have analyzed the expression of this key enzyme in the generation of angiotensin II [37] in a retrospective series of 144 renal neoplasms. The immunohistochemical analysis has corroborated the exclusive location of this peptidase in tumor vessels and has shown a higher immunostaining in CCRCC, the most aggressive renal tumor subtype [3] and, specifically, in high grade cases.

On the other hand, we also have analyzed the expression of APA, another key peptidase of RAS that converts Ang II to Ang III [38]. Inversely to that observed with ACE, this enzyme was expressed in CCRCC cells but not in blood vessels. Moreover, APA expression was lower in larger and higher grade tumors, and the loss of expression was correlated with worse survival. A similar decreasing pattern of APA expression was reported in gynecologic malignancies and indicated that this enzyme may have a tumor suppressor role by degrading Ang II [39,40].

Taking these results into account, we hypothesize that the higher ACE expression in tumor vessels and the lower APA expression in CCRCC tumor cells could lead to an accumulation of Ang II in tumor microenvironment, thereby stimulating angiogenesis and promoting tumor growth and invasiveness. Further studies are needed to examine this hypothesis and clarify the underlying mechanism of action of RAS inhibitors in the enhancement of the antiangiogenic effects of VEGF-targeted therapies [12,14,15,17,20].

Ang 1–7 is a bioactive peptide of RAS mainly generated from Ang II by ACE2, and alternatively from Ang I and Ang 1–9 by NEP/CD10 [37]. It is generally accepted that Ang 1–7 has counter-regulatory effects on many of the events induced by Ang II [7]. Thus, in non-neoplastic renal diseases this peptide inhibits proinflammatory and profibrotic processes that lead to renal damage and ACEi and ARBs have local tissue effects restoring imbalances between Ang II/AT1 and Ang 1-7/Mas receptor axis [41,42]. Furthermore, it has been described in several solid tumors that Ang 1–7 inhibits angiogenesis and tumor progression, and suggested that the balance between two axis may be important in determining if tumors gain an angiogenic and invasive phenotype [8,10,11,19,43].

In this context, it might be expected that Ang 1–7 has an antitumor effect in renal tumors. However, a recent study demonstrated that this peptide increases metastatic potential of RCC cells through its Mas receptor and AKT signaling pathways [18]. Consistent with these findings, we observed that ACE2 and NEP/CD10 expression was higher in proximal nephron-derived carcinomas (CCRCC and PRCC), which are more aggressive than distal-nephron derived carcinomas (ChRCC) [3]. Moreover, both peptidases were highly expressed in higher grade CCRCCs and NEP/CD10 was independently correlated with worse patients’ survival.
Taken together, these results suggest a different role for the Ang 1–7 axis in renal cancer and, therefore, that RAS imbalances in carcinogenetic processes are tumor-specific [8,10,11,18].

The best known function of peptidases is the conversion of bioactive peptides [44]. However, these enzymes can also regulate cell growth, differentiation and signal transduction of many cell systems by degrading extracellular matrix molecules and directly participating in the intracellular signaling as receptors [44–46]. The present study and other previous [21–25] have described that angiotensin-regulating peptidases show different expression and activity patterns in RCCs when compared with the non-tumor surrounding tissue or when stratified by tumor aggressiveness. For example, ACE, ACE2 and NEP/CD10 activity was markedly decreased in renal tumors with respect to normal tissues [21–25]. However, ACE activity [24] and expression, and NEP/CD10 and ACE2 expression was higher in high grade CCRCCs. Therefore, it should be taken into account that the role of these peptidases in the different stages of renal cancer could be due to the sum of its different biological actions or, rather, to its net result [44–46].

Angiotensin-regulating peptidases can be secreted to the extracellular space and appear in serum [44]. The comparative studies of peptidase profiles among cancer patients and control subjects have yielded significant results in several studies [47–49]. In our study, NEP/CD10, ACE2 and APA activity was higher in renal cancer patients than in healthy controls. This result agrees with those described in pancreatic and colorectal cancer [48,49] but it is opposite to that demonstrated in breast cancer [47], which suggests that tumor-specific changes of angiotensin-regulating enzymes occur also in serum of cancer patients.

Correlation among serum values of RAS enzymes and classic histopathological parameters for tumor aggressiveness and survival have pointed to these proteins as useful biomarkers for helping in screening, diagnosis, staging, prognosis and monitoring cancer therapy [47–52]. Our results support this idea. On the one hand, ACE activity was lower in serum of high grade and metastatic CCRCC patients. On the other, NEP/CD10 activity was lower in serum of CCRCC patients with high UISS and SSIGN scores. These scales predict patients' relapse probability [28,29] and, interestingly, Kaplan-Meier curves performed with a median follow-up of 32 months corroborated this result. Further studies with higher number of patients with longer follow-ups would be advisable to confirm the prognostic significance of these data.

The origin of these circulating peptidases in neoplastic diseases is still controversial. The main hypothesis places the origin in tumor microenvironment. However, other sources (such as immune system, liver and spleen) have been also suggested [44,52] since serum peptidase levels and activity don’t usually reflect parallelisms which occur in tumor tissues [44,47,48,52,53]. For example, in this and in a previous work [24], we observed that ACE expression and activity was higher in more aggressive CCRCCs, while serum ACE activity in CCRCC patients was lower. A similar negative correlation was observed with NEP/CD10. Besides, serum APA and ACE2 activity was similar in CCRCC patients with different prognosis while protein expression was significantly altered in aggressive tumors from patients with bad prognosis. This phenomenon needs further clarification because the source of serum peptidases seems critical to validate these enzymes as reliable markers of diagnosis and prognosis in patients with cancer [44,52,53,54].

In conclusion, the present study shows that ACE in tumor vessels and APA, ACE2 and NEP/CD10 in tumor cells are differentially expressed in different renal tumor subtypes, and that the presence/absence of these enzymes is significantly associated with tumor aggressiveness and poor outcome of patients with CCRCC. Furthermore, serum activity of NEP/CD10, ACE2 and APA is higher in RCC patients than in healthy subjects and ACE and NEP/CD10 activity is negatively correlated with CCRCC patients' prognosis. These results favor the possibility of a metabolic imbalance of iRAS and a role of angiotensin-regulating peptidases in
renal neoplastic diseases. A better understanding of the pathophysiological role of these enzymes in these proliferative disorders will be helpful for designing effective diagnostic, prognostic and therapeutic tools for renal neoplasms.

Supporting information
S1 Table. Summary table of the antibodies employed for angiotensin converting enzymes immunohistochemical detection.

Acknowledgments

Grants
This work was partially funded by Grant SAF2013-48812-R from Ministerio de Economía y Competitividad (Spain), IT 8-11/13 from de Basque Government and UFI 11/44 from de University of the Basque Country (UPV/EHU).

The current work has been developed as PhD project of PE and MB, who are recipients of a Predoctoral Fellowship from the Basque Government (Exp n˚ PRE_2013_1_762 and PRE_2015_2_0148)

Author Contributions

Conceptualization: Peio Errarte, José I. López, Gorka Larrinaga.

Formal analysis: Peio Errarte, Charles H. Lawrie, Gorka Larrinaga.

Funding acquisition: Itxaro Perez, José I. López, Gorka Larrinaga.

Investigation: Peio Errarte, Maider Beitia, Itxaro Perez, Lorea Manterola.

Methodology: Peio Errarte, Maider Beitia, Lorea Manterola.

Project administration: José I. López, Gorka Larrinaga.

Resources: Jon Danel Solano-Iturri, Julio Calvete-Candenas, Miguel Unda, José I. López.

Supervision: Charles H. Lawrie, Julio Calvete-Candenas, José I. López.

Validation: Peio Errarte, Maider Beitia, Lorea Manterola, Charles H. Lawrie.

Visualization: Peio Errarte, José I. López, Gorka Larrinaga.

Writing – original draft: Peio Errarte, José I. López, Gorka Larrinaga.

Writing – review & editing: Peio Errarte, Lorea Manterola, Charles H. Lawrie, Julio Calvete-Candenas, José I. López, Gorka Larrinaga.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7–30. https://doi.org/10.3322/caac.21332 PMID: 26742998

2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765–781. https://doi.org/10.1016/j.ejca.2009.12.014 PMID: 20116997

3. MacLennan GT and Cheng L. Neoplasms of the kidney (2014). In: Urologic Surgical Pathology 2014; edited by Bostwick DG and Cheng L, 3rd edn. Saunders, Philadelphi.a. 76–156.

4. López-Beltrán A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798–805. https://doi.org/10.1016/j.eururo.2005.11.035 PMID: 16442207
5. Mourad WF, Dutcher J, Ennis RD. State-of-the-art management of renal cell carcinoma. *Am J Clin Oncol* 2014; 37(5): 498–505. https://doi.org/10.1097/COC.0b013e31825d5522 PMID: 22868246

6. Lam JS, Shvarts O, Leppert JT, Figlin RA, Beldegrun AS: Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. *J Urol* 2005; 173(6): 1853–1862. https://doi.org/10.1097/01.ju.0000165693.68449.c3 PMID: 15879764

7. Fyhquist F, Sajinomaa O. Renin-angiotensin system revisited. *J Intern Med* 2008; 264(3):224–36. https://doi.org/10.1111/j.1365-2796.2008.01981.x PMID: 18793332

8. George AJ, Thomas WG, Hannan RD: The renin-angiotensin system and cancer: old dog, new trick. *Nat Rev Cancer* 2010; 10(11):745–759. https://doi.org/10.1038/nrc2945 PMID: 20966920

9. Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. *Nat Rev Endocrinol* 2015; 4: 242–52.

10. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. *Carcinogenesis* 2008; 29: 1675–84. https://doi.org/10.1039/carcin171 PMID: 18632755

11. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S, Sánchez-Corona J. The renin-angiotensin system meets the hallmarks of cancer. *J Renin Angiotensin Aldosterone Syst* 2015; 16(2): 227–33. https://doi.org/10.1177/1470320315496858 PMID: 23934336

12. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. *Ann Oncol* 2015; 26(6): 1128–33. https://doi.org/10.1093/annonc/mdv147 PMID: 25735198

13. Keizman D, Huang P, Eisenberg MA, Pili R, Kim JJ, Antonarakis ES et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. *Eur J Cancer* 2011; 47(13): 1955–61. https://doi.org/10.1016/j.ejca.2011.04.019 PMID: 21600760

14. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hannvik OP, Sabbisetti VS et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. *Clin Cancer Res* 2015; 21(11): 2471–9. https://doi.org/10.1158/1078-0432.CCR-14-2332 PMID: 25724518

15. Araújo WF, Naves MA, Ravani-JN, Schor N, Teixeira VP. Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. *Urol Oncol* 2015; 33(9): 389.e1–7.

16. Dolley-Hitz T, Jouan F, Martin B, Mottier S, Edeline J, Moranne O et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? *Br J Cancer* 2010; 23; 103(11): 1698–705. https://doi.org/10.1038/sj.bjc.6605866 PMID: 21102591

17. Verhoest G, Dolley-Hitz T, Jouan F, Belaud-Rotureau MA, Oger E, Lavenu A, et al. Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma. *Biomed Res Int* 2014; 901371, https://doi.org/10.1155/2014/901371 PMID: 24967411

18. Zheng S, Yang Y, Song R, Yang X, Liu H, Ma Q et al. Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. *Biochem Biophys Res Commun* 2015; 460(2): 333–40. https://doi.org/10.1016/j.bbrc.2015.03.035 PMID: 25783053

19. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1–7), an endogenous antiangiogenic hormone. *Clin Cancer Res* 2009; 15(23): 7398–404. https://doi.org/10.1158/1078-0432.CCR-09-1957 PMID: 19920106

20. Tatokoro M, Fuji Y, Kawakami S, Saito K, Koga F, Matsuoka Y et al. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. *Cancer Sci* 2011; 102(1):137–43. https://doi.org/10.1111/j.1349-7006.2010.01756.x PMID: 20973869

21. Blanco L, Perez I, Sanz B, Gil J, López JI, Ugalde A et al. Changes in cell-surface peptidase activity in papillary renal cell carcinoma. *Anticancer Res* 2010; 30(4): 1137–1141. PMID: 20530419

22. Blanco L, Sanz B, Perez I, Sánchez CE, Cándenas ML, Pinto FM et al. Altered glutamyl-aminopeptidase activity and expression in renal neoplasms. *BMC Cancer* 2014; 30(14): 386.

23. Larrinaga G, Blanco L, Sanz B, Perez I, Gil J, Unda M et al. The impact of peptidase activity on clear cell renal cell carcinoma survival. *Am J Physiol Renal Physiol* 2012; 303(12): 1584–1591.

24. Larrinaga G, Pérez I, Sanz B, Blanco L, López JI, Cándenas ML et al. Angiotensin-converting enzymes (ACE1 and ACE2) are downregulated in renal tumors. *Regul Pept* 2010; 165: 218–223. https://doi.org/10.1016/j.regpep.2010.07.170 PMID: 20692300

25. Varona A, Blanco L, López JI, Gil J, Agirregoitia E, Izrazusta J et al. Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. *Am J Physiol-Renal Physiol* 2007; 292: 780–788.
26. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 2010; 7th Edition, Springer, New York.

27. Furhman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 1982; 6: 655–663. PMID: 7180965

28. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D et al. Improved prognostication of renal cell carcinoma using an integrated staging system. *J Clin Oncol.* 2001; 19: 1649–1657. https://doi.org/10.1200/JCO.2001.19.6.1649 PMID: 11250993

29. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. *J Urol.* 2002; 168: 2395–2400. PMID: 12441925

30. Florentin D, Sassi A, Roques BP. A highly sensitive fluorimetric assay for "enkephalinalase", a neutral metalloendopeptidase that releases Tyr-Gly-Gly from enkephalins. *Anal Biochem* 1984; 141: 62–69. PMID: 688140

31. Tobe H, Kojima F, Aoyagi T, Umezawa H. Purification by affinity chromatography using amastatin and properties of aminopeptidase A from pig kidney. *Biochim Biophys Acta* 1980; 613(2): 459–468. PMID: 744199

32. Sentandreu MA, Toldrá F. A fluorescence based protocol for quantifying angiotensin-converting enzyme activity. *Nat Protoc* 2006; 1(5): 2423–2427. https://doi.org/10.1038/nprot.2006.349 PMID: 17406486

33. Yan ZH, Ren KJ, Wang Y, Chen S, Brock TA, Rege AA. Development of intramolecularly quenched fluorescent peptides as substrates of angiotensin converting enzyme 2. *Anal Biochem* 2003; 312: 141–147. PMID: 12531198

34. Siddiqui SA, Frank I, Leibovich BC, Cheville JC, Lohse CM, Zincke H, Blute ML. Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. *J Urol* 2006; 177: 59–62.

35. Zhong Y, Chen EY, Liu R, Chuang PY, Mallipattu SK, Tan CM, Clark NR, Deng Y, Klotman PE, Ma’ayan A, He JC. Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. *J Am Soc Nephrol* 2013; 24(5): 801–11. https://doi.org/10.1681/ASN.2012060590 PMID: 23559582

36. Escudier B, Szczylk C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. *Nat Rev Clin Oncol* 2012; 10; 9(6): 327–37. https://doi.org/10.1038/nrclinonc.2012.59 PMID: 22470996

37. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. *Biochem J* 2004; 383 (Pt 1): 45–51. https://doi.org/10.1042/BJ20040634 PMID: 15283675

38. Wolf G, Mentzel S, Assmann KJ. Aminopeptidase A: a key enzyme in the intrarenal degradation of angiotensin II. *Experimental Nephrology* 1997; 5(5): 364–369.

39. Ino K, Shibata K, Kajiyama H, Kikkawa F, Mizutani S. Regulatory role of membrane-bound peptidases in the progression of gynecologic malignancies. *Biochem* 2004; 385(8): 683–90. https://doi.org/10.1515/BC.2004.084 PMID: 15449704

40. Ino K, Shibata K, Yamamoto E, Kajiyama H, Nawa A, Mabuchi Y et al. Role of the renin-angiotensin system in gynecologic cancers. *Curr Cancer Drug Targets* 2011; 11(4): 405–11. PMID: 21395551

41. Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. *Int J Hypertens* 2012; 2012037315. https://doi.org/10.1155/2012/307315 PMID: 22121476

42. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin-angiotensin system. *J Endocrinol* 2013; 216(2): R1–R17. https://doi.org/10.1530/JOE-12-0341 PMID: 23092879

43. Soto-Pantoja DR, Menon J, Gallagher PE and Tallant EA. Angiotensin-(1–7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. *Mol Cancer Ther* 2009; 8, 1676–1683. https://doi.org/10.1158/1535-7163.MCT-09-0161 PMID: 19509262

44. Carl-McGrath S, Lendeckel U, Ebert M, Röcken C. Ectopeptidases in tumour biology: A review. *Histol Histopathol* 2006; 21: 1339–1353. https://doi.org/10.14670/HH-21.1339 PMID: 16977585

45. Lamberton D, Clarke NE, Turner AJ. Not just angiotensinas es: new roles of the angiote nsin-converting enzymes. *Cell Mol Life Sci* 2010; 67: 89–98. https://doi.org/10.1007/s00018-009-0152-x PMID: 19763395

46. Sumimoto M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. *Biochim Biophys Acta* 2005; 1751(1): 52–9. https://doi.org/10.1016/j.bjapa.2004.11.001 PMID: 16054017
47. Ramírez-Expósito MJ, Carrera-González MdP, Mayas MD, Dueñas B, Martínez-Ferrol J, Martínez-Martos JM. Neoadjuvant chemotherapy modifies serum angiotensinase activities in women with breast cancer. *Maturitas* 2012; 72(1): 79–83. https://doi.org/10.1016/j.maturitas.2012.02.007 PMID: 22424590

48. Larrinaga G, Blanco L, Perez I, Sanz B, Errarte P, Beitia M et al. Prolyl endopeptidase activity is correlated with colorectal cancer prognosis. *Int J Med Sci*. 2014; 11: 199–208. https://doi.org/10.7150/ijms.7178 PMID: 24465166

49. Pang L, Zhang N, Xia Y, Wang D, Wang G, Meng X. Serum APN/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer. *Oncotarget*. 2016; 7(47): 77854–77864. https://doi.org/10.18632/oncotarget.12835 PMID: 27788483

50. Kälin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, et al. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. *Eur Urol*. 2011; 60(6): 1235–43. https://doi.org/10.1016/j.eururo.2011.06.038 PMID: 21741162

51. Sasaki T, Kuniyasu H, Luo Y, Fujiwara R, Kitayoshi M, Tanabe E et al. Serum CD10 is associated with liver metastasis in colorectal cancer. *J Surg Res*. 2014; 192(2): 390–4. https://doi.org/10.1016/j.jss.2014.05.071 PMID: 24972738

52. Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L et al. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24. *Clin Lung Cancer*. 2015; 16(6): e189–201. https://doi.org/10.1016/j.cllc.2015.05.002 PMID: 26081815

53. Cordero O, Salgado F, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. *Cancer Immunol Immunother* 2009; 58:1723–47. https://doi.org/10.1007/s00262-009-0728-1 PMID: 19557413

54. Larrinaga G, Perez I, Sanz B, Beitia M, Errarte P, Fernández A et al. Dipeptidyld-peptidase IV activity is correlated with colorectal cancer prognosis. *PLoS One* 2015; 10(3):e0119436. https://doi.org/10.1371/journal.pone.0119436 PMID: 25790122